GSK US Pharma Head Steps Down
Jack Bailey, president, US Pharmaceuticals, GlaxoSmithKline, will step down from his position at the end of 2019 and will be succeeded by a Merck KGaA executive.
On Aug. 12, 2019, GlaxoSmithKline (GSK) announced that Jack Bailey, president, US Pharmaceuticals, will be stepping down from his role at the end of 2019. Bailey will be succeeded by Maya Martinez-Davis, currently regional president, Latin America Region at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.
“Jack is an exceptional leader who has made a very significant contribution to the success of GSK during his decade of leadership in the US,” said Luke Miels, president, Global Pharmaceuticals, GSK, in a company press release. “As we continue to grow and reshape our business globally, we are pleased to have found a leader in Maya who will bring a valuable US experience and deep therapy area expertise to expanding our specialty care capabilities and market presence.”
Prior to her role as regional president, Latin America Region, Martinez-Davis previously held the roles of senior vice-president, Global Oncology, at EMD Serono and had spent 13 years at Pfizer leading various business units around the world including Oncology and Vaccines.
Martinez-Davis will join GSK in mid-September 2019 and will assume responsibility of the US Pharmaceuticals business at GSK on Jan. 1, 2020. Bailey will remain as strategic consultant to GSK on the US external environment through 2020.
Source: GlaxoSmithKline
British Patient Capital Invests £10 Million in Maxion Therapeutics, Part of Series A Financing Round
March 27th 2025The £10 million (US$13 million) investment is part of a larger £58 million (US$75 million) Series A financing round to be used for the development of Maxion Therapeutics’ preclinical lead program for treating inflammatory diseases.
